

# CITATION REPORT

List of articles citing

The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study

DOI: 10.1017/S0007114515002433

British Journal of Nutrition, 2015, 114, 796-803.

Source: <https://exaly.com/paper-pdf/60187474/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
118	Herbs to treat liver diseases: More than placebo?. <b>2015</b> , 6, 136-138		6
117	The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. <b>2015</b> , 15, 25		23
116	Challenges in Analyzing the Biological Effects of Resveratrol. <i>Nutrients</i> , <b>2016</b> , 8,	6.7	37
115	Prevention of Nonalcoholic Fatty Liver Disease (NAFLD) Progression to Nonalcoholic Steatohepatitis (NASH) by Modification of Lifestyle and Dietary Supplements. <b>2016</b> , 2,		1
114	In Search of New Therapeutic Targets in Obesity Treatment: Sirtuins. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	28
113	Resveratrol and Cardiovascular Diseases. <i>Nutrients</i> , <b>2016</b> , 8,	6.7	231
112	Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials. <b>2016</b> , 11, e0161792		28
111	New Insights on the Use of Dietary Polyphenols or Probiotics for the Management of Arterial Hypertension. <i>Frontiers in Physiology</i> , <b>2016</b> , 7, 448	4.6	30
110	The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications. <b>2016</b> , 4,		40
109	Dietary supplementation in patients with alcoholic liver disease: a review on current evidence. <b>2016</b> , 15, 348-60		22
108	Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals. <b>2016</b> , 1-19		
107	Resveratrol Supplementation and Oxidative/Anti-Oxidative Status in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study. <b>2016</b> , 47, 304-9		72
106	Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance. <b>2016</b> , 4, e12877		26
105	At the interface of antioxidant signalling and cellular function: Key polyphenol effects. <b>2016</b> , 60, 1770-88		44
104	The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. <b>2016</b> , 17, 1329-1340		39
103	Adherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of Nonalcoholic Fatty Liver Disease. <b>2016</b> , 67, 1024-9		50
102	Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. <b>2016</b> , 101, 4322-4328		77

101	Deoxyrhapontigenin, a Natural Stilbene Derivative Isolated From <i>Rheum undulatum</i> L. Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Breast Cancer Cells. <b>2016</b> , 15, NP44-NP52	11
100	Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. <b>2016</b> , 67, 461-9	52
99	Nut consumption and total and cause-specific mortality: results from the Golestan Cohort Study. <b>2017</b> , 46, 75-85	30
98	The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. <b>2017</b> , 83, 88-95	54
97	Antioxidant effects of resveratrol in the cardiovascular system. <b>2017</b> , 174, 1633-1646	248
96	Adipose tissue NAD biology in obesity and insulin resistance: From mechanism to therapy. <b>2017</b> , 39, 1600227	37
95	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. <b>2017</b> , 8, 240-252	85
94	Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths. <b>2017</b> , 35, 326-343	2
93	The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis. <b>2017</b> , 31, 108-114	62
92	Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. <b>2017</b> , 34, 108-117	52
91	Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. <b>2017</b> , 97, 2327-2332	29
90	Emerging roles of SIRT1 in fatty liver diseases. <b>2017</b> , 13, 852-867	146
89	Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. <b>2017</b> , 14, 60	88
88	Beneficial effects of acute trans-resveratrol supplementation in treated hypertensive patients with endothelial dysfunction. <b>2018</b> , 40, 218-223	28
87	Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. <b>2018</b> , 130, 213-240	97
86	A Comparison of the Effectiveness of Silibinin and Resveratrol in Preventing Alpha-Amanitin-Induced Hepatotoxicity. <b>2018</b> , 122, 633-642	8
85	Effect of resveratrol on lipid profile: An updated systematic review and meta-analysis on randomized clinical trials. <b>2018</b> , 129, 141-150	62
84	Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. <b>2018</b> , 37, 223-233	32

83	The Effects of Onion Consumption on Prevention of Nonalcoholic Fatty Liver Disease. <b>2018</b> , 33, 75-80		18
82	Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials. <b>2018</b> , 58, 3016-3029		21
81	Bioavailability of resveratrol: Possibilities for enhancement. <b>2018</b> , 11, 71-77		38
80	Resveratrol, Metabolic Syndrome, and Gut Microbiota. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	107
79	Dietary Composition and Cardiovascular Risk: A Mediator or a Bystander?. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	19
78	Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases. <b>2018</b> , 9, 2160		96
77	Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. <b>2018</b> , 6,		24
76	Resveratrol and Related Stilbenoids, Nutraceutical/Dietary Complements with Health-Promoting Actions: Industrial Production, Safety, and the Search for Mode of Action. <b>2018</b> , 17, 808-826		29
75	Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system. <b>2018</b> , 17, 178		45
74	An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease. <b>2018</b> , 23,		16
73	Preparation and Characterization of Resveratrol Loaded Pectin/Alginate Blend Gastro-Resistant Microparticles. <b>2018</b> , 23,		10
72	No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. <b>2018</b> , 20, 2504-2509		15
71	The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2019</b> , 26, 305-319		22
70	ESPEN guideline on clinical nutrition in liver disease. <b>2019</b> , 38, 485-521		202
69	Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial. <b>2019</b> , 44, 204-209		13
68	Blond and blood juice supplementation in high fat diet fed mice: effect on antioxidant status and DDAH/ADMA pathway.. <b>2019</b> , 9, 11406-11412		1
67	How efficient is resveratrol as an antioxidant of the Mediterranean diet, towards alterations during the aging process?. <b>2019</b> , 53, 1101-1112		22
66	What are the main areas of focus to prevent or treat non-alcoholic fatty liver disease?. <b>2019</b> , 20, 271-277		2

65	Polyphenol intakes and risk of impaired lipid profile, elevated hepatic enzymes and nonalcoholic fatty liver disease. <b>2019</b> , 49, 903-910		7
64	Health benefits of resveratrol: Evidence from clinical studies. <b>2019</b> , 39, 1851-1891		167
63	Dietary Interventions in Fatty Liver. <b>2019</b> , 245-255		
62	Research on FAGP Alarm System Based on Multi-Temperature Sensor. <b>2019</b> ,		
61	The Bioprotective Effects of Polyphenols on Metabolic Syndrome against Oxidative Stress: Evidences and Perspectives. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2019</b> , 2019, 6713194	6.7	35
60	The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. <b>2019</b> , 73, 441-449		28
59	Mechanisms underlying the metabolic beneficial effect of curcumin intervention: Beyond anti-inflammation and anti-oxidative stress. <b>2019</b> , 13, 1-5		8
58	Galactose intake is related to nonalcoholic fatty liver disease. <b>2019</b> , 49, 359-367		3
57	Resveratrol supplementation and flow-mediated dilation: a systematic review. <b>2019</b> , 49, 580-591		3
56	Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. <b>2019</b> , 20, 487-498		32
55	Effect of resveratrol on blood pressure: A systematic review and meta-analysis of randomized, controlled, clinical trials. <b>2019</b> , 59, 1605-1618		64
54	Resveratrol Metabolites Are Able to Reduce Steatosis in Cultured Hepatocytes. <b>2020</b> , 13,		5
53	Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials. <b>2020</b> , 5, e98-e111		7
52	Bioactive Compounds for the Management of Hypertriglyceridemia: Evidence From Clinical Trials and Putative Action Targets. <b>2020</b> , 7, 586178		1
51	ESPEN practical guideline: Clinical nutrition in liver disease. <b>2020</b> , 39, 3533-3562		52
50	Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease-A Meta-Analysis. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	15
49	. <b>2020</b> , 45,		2
48	Targeting Abdominal Obesity and Its Complications with Dietary Phytoestrogens. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	15

47	The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. <b>2020</b> , 19, 25		20
46	Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	58
45	Fine wine or sour grapes? A systematic review and meta-analysis of the impact of red wine polyphenols on vascular health. <b>2021</b> , 60, 1-28		11
44	Effects of resveratrol supplementation on liver enzymes: A systematic review and meta-analysis of randomised controlled trials. <b>2021</b> , 75, e13692		1
43	Beneficial Effects of Plant-Derived Natural Products on Non-alcoholic Fatty Liver Disease. <b>2021</b> , 1308, 257-272		2
42	Hepatoprotective activity of natural compounds and plant extracts in nonalcoholic fatty liver disease. <b>2021</b> , 83-103		
41	Polyphenols and their effects on metabolic syndromes and other CVD risk factors. <b>2021</b> , 253-267		
40	Resveratrol. <b>2021</b> , 349-378		1
39	Nutraceuticals for Non-alcoholic Fatty Liver Disease. <b>2021</b> , 141-165		
38	Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	24
37	Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota. <b>2021</b> , 12, 611323		6
36	The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. <b>2021</b> , 100, e24884		2
35	Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development. <b>2021</b> , 18, 333-353		1
34	Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	6
33	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. <b>2021</b> , 7, CD013157		2
32	Adipogenesis and therapeutic potentials of antiobesogenic phytochemicals: Insights from preclinical studies. <b>2021</b> , 35, 5936-5960		2
31	Hypoglycemic Effect of Resveratrol: A Systematic Review and Meta-Analysis. <b>2021</b> , 10,		6
30	Hepatic Biomarkers in Diabetes as Modulated by Dietary Phytochemicals. <b>2017</b> , 957-975		3

29	No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. <b>2020</b> , 90, 279-289		10
28	Current understanding and controversies on the clinical implications of fibroblast growth factor 21. <b>2021</b> , 58, 311-328		5
27	Natural Products from Mediterranean Diet: From Anti-hyperlipidemic Agents to Dietary Epigenetic Modulators. <b>2019</b> , 20, 825-844		5
26	Influence of Resveratrol on Sphingolipid Metabolism in Hepatocellular Carcinoma Cells in Lipid Overload State. <b>2019</b> , 19, 121-129		7
25	Effects of 8 weeks of aerobic training and resveratrol on physical fitness, insulin resistance, liver function, and blood pressure in T2DM elderly women. <b>2016</b> , 27, 507-522		1
24	Functional Foods for Type 2 Diabetes. <b>2016</b> , 3, 278-297		2
23	Administration of low-dose resveratrol attenuated hepatic inflammation and lipid accumulation in high cholesterol-fructose diet-induced rat model of nonalcoholic fatty liver disease. <b>2020</b> , 63, 149-155		3
22	Egg consumption and risk of non-alcoholic fatty liver disease. <b>2017</b> , 9, 503-509		23
21	Effect of resveratrol supplementation on biomarkers associated with atherosclerosis in humans. <b>2021</b> , 46, 101491		0
20	Nigella sativa and Non-Alcoholic Fatty Liver Disease: A Review of the Current Evidence. <b>2018</b> , In Press,		
19	Dietary Strategies to Improve Cardiovascular Health: Focus on Increasing High-Density Lipoprotein Functionality. <b>2021</b> , 8, 761170		2
18	CARDIOVASCULAR CHANGE IN ATHLETES AT DIFFERENT TRAINING STATUS LEVELS. <i>Revista Brasileira De Medicina Do Esporte</i> , <b>2022</b> , 28, 31-33	0.5	0
17	Curcumin and Weight Loss: Does It Work?. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	3
16	Role of natural products as therapeutic option against nonalcoholic fatty liver disease. <b>2022</b> , 289-305		
15	Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review.. <i>Frontiers in Physiology</i> , <b>2022</b> , 13, 795980	4.6	1
14	CALISTHENICS EXERCISES TO INTERVENE IN OBESITY AND DIABETES IN MIDDLE-AGED PEOPLE. <i>Revista Brasileira De Medicina Do Esporte</i> , <b>2022</b> , 28, 85-88	0.5	
13	Therapeutic potential of resveratrol in diabetic nephropathy according to molecular signaling.. <i>Current Molecular Pharmacology</i> , <b>2021</b> ,	3.7	1
12	A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2022</b> , 2022, 1-15	6.7	0

11	Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial.. <i>BMC Cardiovascular Disorders</i> , <b>2022</b> , 22, 212	2.3	0
10	A Review on Rhubarb-Derived Substances as Modulators of Cardiovascular Risk Factors: A Special Emphasis on Anti-Obesity Action. <i>Nutrients</i> , <b>2022</b> , 14, 2053	6.7	1
9	The Clock-NAD + -Sirtuin connection in nonalcoholic fatty liver disease. <i>Journal of Cellular Physiology</i> ,	7	1
8	A new nutraceutical (Livogen Plus ) improves liver steatosis in adults with non-alcoholic fatty liver disease. <b>2022</b> , 20,		2
7	Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway. 13,		0
6	Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. 13,		2
5	The effect of natural products use on blood pressure in Iran: Systematic review and meta-analysis. <b>2022</b> , 9, 152		0
4	The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta-analysis of randomized controlled trials.		0
3	Dark Sweet Cherry ( <i>Prunus avium</i> ) Supplementation Reduced Blood Pressure and Pro-Inflammatory Interferon Gamma (IFN $\gamma$ ) in Obese Adults without Affecting Lipid Profile, Glucose Levels and Liver Enzymes. <b>2023</b> , 15, 681		0
2	Nutrition in liver disease. <b>2023</b> , 87-134		0
1	Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management. <b>2023</b> , 38, 144-160		0